clinical trial · NCT04675333
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Head and Neck CancerHead and Neck Squamous Cell CarcinomaevorpaceptpembrolizumabCisplatin/Carboplatin; 5FU
brief summary
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
started
May 10, 2021
primary completion
Mar 3, 2025
completion
Jun 30, 2026
last updated
Aug 3, 2025
detailed description
This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease. The study comprises of an initial safety lead-in followed by a randomized portion.
official title
A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol